June 17, 2011
The Colorado Bioscience Association has published this fact sheet that includes information on the biotechnology industry in Colorado and comparative rankings with the national biotechnology industry in the United States.
Read More
June 17, 2011
October 4-5, 2011
BayBio and BIOCOM
Crowne Plaza Cabana
Palo Alto, CA
Read More
June 17, 2011
August 8-9, 2011
San Diego Hilton Mission Bay
San Diego, CA
Read More
June 17, 2011
June 27-29, 2011
UC San Diego, Rady School of Management
La Jolla, CA
Read More
June 17, 2011
California’s biomedical industry has grown organically from ideas first germinated in the state’s universities. Through technology transfer, entrepreneurial commitment and investor financing, basic science discoveries have led to breakthrough technologies to better understand, diagnose, treat and cure a broad range of medical disorders.
Read More
June 17, 2011
The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More
June 17, 2011
The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More
June 17, 2011
One somewhat overlooked element of the Obama administration’s proposed federal budget is its desire to create the first regulatory process for government approval of so-called “follow-on biologics,” or generic versions of drugs manufactured by living organisms. These medicines are often used in treatments such as cancer, anemia, psoriasis and rare diseases, where little room for error exists.
Read More
